A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Molecular Pharmacology

• Publication date

  2004-09-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/MOL.104.000638PMID 15322256
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recruitment and Activation of Phospholipase Cγ1 by Vascular Endothelial Growth Factor Receptor-2 Are Required for Tubulogenesis and Differentiation of Endothelial Cells*

  2003cited by this paper
• Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• A novel early chorioallantoic membrane assay demonstrates quantitative and qualitative changes caused by antiangiogenic substances.

  2003cited by this paper
• Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis.

  2003cited by this paper
• Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

  2003cited by this paper
• Preferential Topography of Proteins Regulating Vascularization and Apoptosis in a MX1 Xenotransplant After Treatment With Hypoxia, Hyperthermia, Ifosfamide, and Irradiation

  2002cited by this paper
• ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

  2002influential reference
• Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.

  2002influential reference
• Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma.

  2002cited by this paper
• Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice.

  2002cited by this paper
• Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

  2001cited by this paper
• Regulation of phosphoinositide-specific phospholipase C.

  2001cited by this paper
• Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis.

  2001cited by this paper
• Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate.

  2001cited by this paper
• Fibroblast growth factors are required for efficient tumor angiogenesis.

  2000cited by this paper
• Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

  2000cited by this paper
• PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

  2000influential reference
• Molecular and biological properties of vascular endothelial growth factor

  1999cited by this paper
• SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

  1999cited by this paper
• VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells

  1999cited by this paper
• Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.

  1999cited by this paper
• Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro.

  1999cited by this paper
• Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

  1998cited by this paper
• Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells.

  1998cited by this paper
• An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells.

  1998cited by this paper
• A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes.

  1998cited by this paper
• The Vascular Endothelial Growth Factor Receptor KDR Activates Multiple Signal Transduction Pathways in Porcine Aortic Endothelial Cells*

  1997cited by this paper
• Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal.

  1997cited by this paper
• p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells

  1997cited by this paper
• Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways.

  1997cited by this paper
• Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

  1997cited by this paper
• Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.

  1996cited by this paper
• Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1.

  1996cited by this paper
• Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor.

  1996cited by this paper
• Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.

  1995cited by this paper
• Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF.

  1995cited by this paper
• Endothelial receptor tyrosine kinases involved in angiogenesis

  1995cited by this paper
• Automatic vessel segmentation and quantification of the rat aortic ring assay of angiogenesis.

  1995cited by this paper
• Clinical Applications of Research on Angiogenesis

  1995cited by this paper
• Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.

  1994cited by this paper
• Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

  1994cited by this paper
• Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

  1993cited by this paper
• High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.

  1993cited by this paper
• PDGF stimulation of inositol phospholipid hydrolysis requires PLC-gamma 1 phosphorylation on tyrosine residues 783 and 1254.

  1991cited by this paper
• Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro.

  1990cited by this paper
• Theory and Practice of Histotechnology

  1980cited by this paper
• Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors

  1972cited by this paper

• Vessel grafts for tissue engineering revisited—Vessel segments show location‐specific vascularization patterns in ex vivo ring assay

  2021cites this paper
• Antitumor and anti-angiogenic effects of artemisinin on breast tumor xenografts in nude mice.

  2020cites this paper
• Combination therapy of hepatocellular carcinoma by DNA shuffling-based VEGF vaccine and doxorubicin.

  2018cites this paper
• Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents.

  2017cites this paper
• Green synthesis, characterization and anxiolytic, sedative and hypnotic activity of pyrimidine based diazepine derivatives

  2017cites this paper
• Methodological Approach to Use Fresh and Cryopreserved Vessels as Tools to Analyze Pharmacological Modulation of the Angiogenic Growth

  2016cites this paper
• Multifunctional Polymeric Nano-Carriers in Targeted Drug Delivery

  2015cites this paper
• Fluorine Substituted 1,2,4-Triazinones as Potential Anti-HIV-1 and CDK2 Inhibitors

  2014cites this paper
• OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis.

  2013cites this paper
• Design, synthesis, and in vitro antitumor evaluation of novel phenylaminopyrimidine derivatives.

  2013cites this paper
• Controlled release of triamcinolone acetonide from polyurethane implantable devices: application for inhibition of inflammatory-angiogenesis

  2012cites this paper
• Designing and Synthesis of New Fluorine Substituted Pyrimidine-Thion-5-Carbonitriles and the Related Derivatives as Photochemical Probe Agents for Inhibition of Vitiligo Disease

  2012cites this paper
• Theranostic Applications of Nanomaterials in Cancer: Drug Delivery, Image-Guided Therapy, and Multifunctional Platforms

  2011cites this paper
• Recent progress of small molecular VEGFR inhibitors as anticancer agents.

  2011cites this paper
• Reversal of Retinal Vascular Changes Associated with Ocular Neovascularization by Small Molecules: Progress toward Identifying Molecular Targets for Therapeutic Intervention

  2011cites this paper
• Paracrine regulation of angiogenesis by different cell types in the aorta ring model.

  2011cites this paper
• FMS-like tyrosine kinase 3 inhibitors: a patent review

  2011cites this paper
• VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.

  2011cites this paper
• The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis

  2010cites this paper
• Novel Ethyl 2-(1-aminocyclobutyl)-5-(benzoyloxy)-6-hydroxy-pyrimidine-4-carboxylate Derivatives: Synthesis and Anticancer Activities

  2010cites this paper
• Compound K inhibits basic fibroblast growth factor-induced angiogenesis via regulation of p38 mitogen activated protein kinase and AKT in human umbilical vein endothelial cells.

  2010cites this paper
• The aortic ring model of angiogenesis: a quarter century of search and discovery

  2009cites this paper
• Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.

  2009cites this paper
• A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo

  2009cites this paper
• Scalable synthesis of the VEGF-R2 kinase inhibitor JNJ-17029259 using ultrasound-mediated addition of MeLi-CeCl3 to a nitrile.

  2008cites this paper
• Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.

  2008cites this paper
• Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors

  2008cites this paper
• 4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors.

  2008cites this paper
• Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.

  2008cites this paper
• Pyrimidines and their Benzo Derivatives

  2008cites this paper
• 4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation.

  2007cites this paper
• Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1).

  2007cites this paper
• Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer

  2007cites this paper
• Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer

  2007cites this paper
• Gene Therapy Targeted at Angiogenesis and Lymphangiogenesis for Cancer Treatment

  2007cites this paper
• Antiangiogenic agents: an update on small molecule VEGFR inhibitors.

  2007cites this paper
• Efficient Pd-catalyzed synthesis of 2-arylaminopyrimidines via microwave irradiation

  2006cites this paper
• Fluorine in medicinal chemistry: A review of anti-cancer agents

  2006cites this paper
• Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor

  2006cites this paper
• Multi-functional polymeric nanoparticles for tumour-targeted drug delivery

  2006cites this paper
• Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats

  2005cites this paper
• The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.

  2005cites this paper
• (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.

  2005cites this paper
• Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.

  2005cites this paper
• Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.

  2005cites this paper